admin@thryvtrx.com<\/a>.<\/p>\nAbout Thryv’s SGK1 Inhibitors
Thryv Therapeutics is developing a series of potent and selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitors as first-in-class therapies for rare inherited and acquired cardiometabolic diseases with high unmet need. SGK1 is a genetically validated therapeutic target in heart failure that drives major forms of residual risk and poor outcomes in patients despite current therapies, including chronic inflammation, fibrosis, and arrhythmic risk. In heart tissue, SGK1 activation also adversely affects ion channel function and drives QT interval prolongation, contributing to both congenital and acquired forms of Long QT Syndrome.<\/p>\n
Thryv’s lead program is in a Phase 2\/3 trial for Long QT Syndrome, a genetic heart rhythm disease, and has the potential to become the first approved disease-modifying therapy for the condition. THRV-1268, an orally administered SGK1 inhibitor being evaluated in the trial, recently received FDA Fast Track designation, with a potential NDA submission anticipated around 2028. Thryv is also expanding its platform into prevalent acquired diseases, including heart failure, cardiomyopathies, and cardiometabolic syndromes. A Phase 2 trial targeting a high-risk segment of heart failure, which affects approximately 1 million U.S. patients, is expected to begin in 2026.<\/p>\n","protected":false},"excerpt":{"rendered":"Sharing Progress on a Pipeline of First-in-Class SGK1 Inhibitors Targeting High-Risk Cardiovascular Populations MONTREAL, May 12, 2026 \/CNW\/…\n","protected":false},"author":2,"featured_media":64050,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[129],"tags":[34977,8781,34975,34974,34973,34976,223],"class_list":{"0":"post-64049","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ubs","8":"tag-company-presentation","9":"tag-heart-failure","10":"tag-investor-meetings","11":"tag-long-qt-syndrome","12":"tag-sgk1","13":"tag-thryv-therapeutics-inc","14":"tag-ubs"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116561624890365242","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/64049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=64049"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/64049\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/64050"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=64049"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=64049"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=64049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Thryv](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/05\/f6863f6406324a44343eacfbe1de86ba.jpeg\")
<\/a> Thryv Therapeutics Inc. Logo (CNW Group\/Thryv Therapeutics Inc.) <\/p>\n